[
  {
    "ts": null,
    "headline": "Worried About the Economy? 2 No-Brainer Buys to Shield Your Portfolio.",
    "summary": "The Nasdaq Composite (NASDAQINDEX: ^IXIC) and the S&P 500 (SNPINDEX: ^GSPC) sank, shifting in and out of correction territory in the first quarter of the year for one big reason: investors have been worried about the economy.  President Donald Trump is putting tariffs on imports, and economists predict this could lead to higher inflation and a slowdown in growth.  Healthcare companies, for example, may excel since people need their medicines or procedures regardless of the economic backdrop.",
    "url": "https://finnhub.io/api/news?id=b11b5cfefe54fe5c4fe7c7c8061dd61cde67d7c4e60ff6ec91cbdf35bed0594b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743632100,
      "headline": "Worried About the Economy? 2 No-Brainer Buys to Shield Your Portfolio.",
      "id": 133695065,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The Nasdaq Composite (NASDAQINDEX: ^IXIC) and the S&P 500 (SNPINDEX: ^GSPC) sank, shifting in and out of correction territory in the first quarter of the year for one big reason: investors have been worried about the economy.  President Donald Trump is putting tariffs on imports, and economists predict this could lead to higher inflation and a slowdown in growth.  Healthcare companies, for example, may excel since people need their medicines or procedures regardless of the economic backdrop.",
      "url": "https://finnhub.io/api/news?id=b11b5cfefe54fe5c4fe7c7c8061dd61cde67d7c4e60ff6ec91cbdf35bed0594b"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma Avoids Worst-Case Tariff Scenario",
    "summary": "Drugmakers breathed a sigh of relief Wednesday after President Trump didn’t announce pharmaceutical tariffs.  Plus, language in the executive order indicated medicines were exempted from the reciprocal tariffs that Trump did announce.  Drugmakers were combing over the executive order to clarify the exemption language in the executive order and to make sure they won’t be hit by any other tariff provisions, such as the 10% “baseline” tariff.",
    "url": "https://finnhub.io/api/news?id=e56792421f40cd13cbd5b94e4465a2bf24427e7b41aded3c7608a2d37bd75b9a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743631415,
      "headline": "Big Pharma Avoids Worst-Case Tariff Scenario",
      "id": 133695061,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Drugmakers breathed a sigh of relief Wednesday after President Trump didn’t announce pharmaceutical tariffs.  Plus, language in the executive order indicated medicines were exempted from the reciprocal tariffs that Trump did announce.  Drugmakers were combing over the executive order to clarify the exemption language in the executive order and to make sure they won’t be hit by any other tariff provisions, such as the 10% “baseline” tariff.",
      "url": "https://finnhub.io/api/news?id=e56792421f40cd13cbd5b94e4465a2bf24427e7b41aded3c7608a2d37bd75b9a"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider",
    "summary": "The latest trading day saw Johnson & Johnson (JNJ) settling at $155.36, representing a +1.38% change from its previous close.",
    "url": "https://finnhub.io/api/news?id=e29d90b0b839e5cc3a58889106638c4e9bcbac8c1cf9a375130c6727c2e20927",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743630315,
      "headline": "Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider",
      "id": 133695067,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The latest trading day saw Johnson & Johnson (JNJ) settling at $155.36, representing a +1.38% change from its previous close.",
      "url": "https://finnhub.io/api/news?id=e29d90b0b839e5cc3a58889106638c4e9bcbac8c1cf9a375130c6727c2e20927"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance in Late Afternoon Trading",
    "summary": "Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index up 0.4% and the He",
    "url": "https://finnhub.io/api/news?id=173b47b7ec6c269ba32a94c52feb5263b6316d13b722a459235f073f25184151",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743623959,
      "headline": "Sector Update: Health Care Stocks Advance in Late Afternoon Trading",
      "id": 133679119,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index up 0.4% and the He",
      "url": "https://finnhub.io/api/news?id=173b47b7ec6c269ba32a94c52feb5263b6316d13b722a459235f073f25184151"
    }
  },
  {
    "ts": null,
    "headline": "GSK: Under Threat From 'Double Whammy' Of Vaccine Skepticism And Pharma Tariffs",
    "summary": "Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are creating turbulence within the Pharma sector.",
    "url": "https://finnhub.io/api/news?id=8b5a6872f622707437bfacf7a3abc3b4bc02308d2cfdcb04e542ed4d09e9bd4b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743608140,
      "headline": "GSK: Under Threat From 'Double Whammy' Of Vaccine Skepticism And Pharma Tariffs",
      "id": 133673915,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1262992012/image_1262992012.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are creating turbulence within the Pharma sector.",
      "url": "https://finnhub.io/api/news?id=8b5a6872f622707437bfacf7a3abc3b4bc02308d2cfdcb04e542ed4d09e9bd4b"
    }
  },
  {
    "ts": null,
    "headline": "Dow's 115-point rally led by gains for Goldman Sachs, Amazon.com Inc. stocks",
    "summary": "Dow's 115-point rally led by gains for Goldman Sachs, Amazon.com Inc. stocks",
    "url": "https://finnhub.io/api/news?id=21803cd693484d4c9f4cf02fd33326152e0f47b43694659cabd9512b0a318f89",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743601800,
      "headline": "Dow's 115-point rally led by gains for Goldman Sachs, Amazon.com Inc. stocks",
      "id": 133669494,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Dow's 115-point rally led by gains for Goldman Sachs, Amazon.com Inc. stocks",
      "url": "https://finnhub.io/api/news?id=21803cd693484d4c9f4cf02fd33326152e0f47b43694659cabd9512b0a318f89"
    }
  },
  {
    "ts": null,
    "headline": "What's next for Johnson and Johnson after third failed attempt to settle talc laws",
    "summary": "Investing.com -- U.S. Bankruptcy Court Judge Christopher Lopez in the Southern District of Texas rejected a request from Johnson & Johnson's (NYSE:JNJ) subsidiary, Red River Talc, to approve its prepackaged bankruptcy plan.",
    "url": "https://finnhub.io/api/news?id=d6c8ce10d822bcd01fb7feac847ba705afea688ae6ef717237b74695d1a69fc1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743601465,
      "headline": "What's next for Johnson and Johnson after third failed attempt to settle talc laws",
      "id": 133669399,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Investing.com -- U.S. Bankruptcy Court Judge Christopher Lopez in the Southern District of Texas rejected a request from Johnson & Johnson's (NYSE:JNJ) subsidiary, Red River Talc, to approve its prepackaged bankruptcy plan.",
      "url": "https://finnhub.io/api/news?id=d6c8ce10d822bcd01fb7feac847ba705afea688ae6ef717237b74695d1a69fc1"
    }
  },
  {
    "ts": null,
    "headline": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
    "summary": "Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.",
    "url": "https://finnhub.io/api/news?id=fbf07e20289e4278acd6778a8f898025df03a81d8f16fee26f4d06095dd53573",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743598808,
      "headline": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
      "id": 133669401,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.",
      "url": "https://finnhub.io/api/news?id=fbf07e20289e4278acd6778a8f898025df03a81d8f16fee26f4d06095dd53573"
    }
  },
  {
    "ts": null,
    "headline": "Morning Movers: Johnson & Johnson slips after rejection of Talc case settlement",
    "summary": "Stock index futures are experiencing early declines amid investor apprehension surrounding President Donald Trump’s impending “Liberation Day” tariffs, set to be introduced tomorrow. In the commodities market, gold prices have surged to new record highs as investors seek safe-haven assets amid escalating trade tensions. Spot gold briefly surpassed $3,170 per ounce, highlighting the prevailing market anxiety. ​Meanwhile, oil prices have exhibited modest gains. Investors are closely monitoring dev",
    "url": "https://finnhub.io/api/news?id=0fe6e6b4bc20a25c9ba568b91b4716fbecb7ed324947527ea56c5bd84e9b3e10",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743598566,
      "headline": "Morning Movers: Johnson & Johnson slips after rejection of Talc case settlement",
      "id": 133666351,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Stock index futures are experiencing early declines amid investor apprehension surrounding President Donald Trump’s impending “Liberation Day” tariffs, set to be introduced tomorrow. In the commodities market, gold prices have surged to new record highs as investors seek safe-haven assets amid escalating trade tensions. Spot gold briefly surpassed $3,170 per ounce, highlighting the prevailing market anxiety. ​Meanwhile, oil prices have exhibited modest gains. Investors are closely monitoring dev",
      "url": "https://finnhub.io/api/news?id=0fe6e6b4bc20a25c9ba568b91b4716fbecb7ed324947527ea56c5bd84e9b3e10"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership",
    "summary": "NEW BRUNSWICK, N.J., April 02, 2025--Johnson & Johnson (NYSE: JNJ) today announced it has completed its acquisition of Intra-Cellular Therapies, Inc. Intra-Cellular Therapies is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson Innovative Medicine.",
    "url": "https://finnhub.io/api/news?id=e990279925aac6c7adc63c98e031af112f42befe3d1569ac48ded58d8dd414bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743597840,
      "headline": "Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership",
      "id": 133669405,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "NEW BRUNSWICK, N.J., April 02, 2025--Johnson & Johnson (NYSE: JNJ) today announced it has completed its acquisition of Intra-Cellular Therapies, Inc. Intra-Cellular Therapies is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson Innovative Medicine.",
      "url": "https://finnhub.io/api/news?id=e990279925aac6c7adc63c98e031af112f42befe3d1569ac48ded58d8dd414bc"
    }
  },
  {
    "ts": null,
    "headline": "Goldman Sachs, Johnson & Johnson share gains contribute to Dow's nearly 125-point jump",
    "summary": "Goldman Sachs, Johnson & Johnson share gains contribute to Dow's nearly 125-point jump",
    "url": "https://finnhub.io/api/news?id=669f9caacf9d054d907d1d8aa97d244be4c920fcbec0058fae145b9cfb54c0fe",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743592860,
      "headline": "Goldman Sachs, Johnson & Johnson share gains contribute to Dow's nearly 125-point jump",
      "id": 133669984,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Goldman Sachs, Johnson & Johnson share gains contribute to Dow's nearly 125-point jump",
      "url": "https://finnhub.io/api/news?id=669f9caacf9d054d907d1d8aa97d244be4c920fcbec0058fae145b9cfb54c0fe"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Expects Lower Earnings Impact From Intra-Cellular Therapies Acquisition",
    "summary": "Johnson & Johnson (JNJ) expects its pending acquisition of Intra-Cellular Therapies (ITCI) to have a",
    "url": "https://finnhub.io/api/news?id=ff46b1aab5eab09f15c1f68ee546344aeee25fd428c82429ae4531343b87eee8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743590133,
      "headline": "Johnson & Johnson Expects Lower Earnings Impact From Intra-Cellular Therapies Acquisition",
      "id": 133666102,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) expects its pending acquisition of Intra-Cellular Therapies (ITCI) to have a",
      "url": "https://finnhub.io/api/news?id=ff46b1aab5eab09f15c1f68ee546344aeee25fd428c82429ae4531343b87eee8"
    }
  },
  {
    "ts": null,
    "headline": "Trending tickers: Tesla, Johnson & Johnson, CoreWeave, Newsmax and Raspberry Pi",
    "summary": "The latest investor updates on stocks that are trending on Wednesday.",
    "url": "https://finnhub.io/api/news?id=7df74f9acfb8cb98459bcb013fcedf07bd1896e6e30e1921f04c41a816108a36",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743586874,
      "headline": "Trending tickers: Tesla, Johnson & Johnson, CoreWeave, Newsmax and Raspberry Pi",
      "id": 133666083,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The latest investor updates on stocks that are trending on Wednesday.",
      "url": "https://finnhub.io/api/news?id=7df74f9acfb8cb98459bcb013fcedf07bd1896e6e30e1921f04c41a816108a36"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market News For Apr 2, 2025",
    "summary": "Wall Street closed mixed on Tuesday to finish the first trading day of second-quarter 2025 after a choppy session.",
    "url": "https://finnhub.io/api/news?id=93924807f172dccc1bec5b089b3d919fbc2115ab00cf03f1cd676763f4a72099",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743581940,
      "headline": "Stock Market News For Apr 2, 2025",
      "id": 133666104,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Wall Street closed mixed on Tuesday to finish the first trading day of second-quarter 2025 after a choppy session.",
      "url": "https://finnhub.io/api/news?id=93924807f172dccc1bec5b089b3d919fbc2115ab00cf03f1cd676763f4a72099"
    }
  },
  {
    "ts": null,
    "headline": "3 Wide-Moat Dividend Stars For A Championship Portfolio",
    "summary": "3 Wide-Moat Dividend Stars For A Championship Portfolio",
    "url": "https://finnhub.io/api/news?id=f0031775d786a034c935b78b14c00a1196b03f5d3fff00e4483f4e703d9525ea",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743579000,
      "headline": "3 Wide-Moat Dividend Stars For A Championship Portfolio",
      "id": 133665687,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=f0031775d786a034c935b78b14c00a1196b03f5d3fff00e4483f4e703d9525ea"
    }
  },
  {
    "ts": null,
    "headline": "Watch These Johnson & Johnson Levels as Stock Plunges After Judge Rejects Talc Settlement",
    "summary": "Johnson & Johnson shares tumbled Tuesday to lead S&P 500 decliners after the health care giant failed to reach a settlement in liability cases related to its baby powder and other talc products. Monitor these key chart levels.",
    "url": "https://finnhub.io/api/news?id=47043a379ca2efec2f1a18c86572c59fc8100e4510e2c7cbd21da8b38e899ada",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743561941,
      "headline": "Watch These Johnson & Johnson Levels as Stock Plunges After Judge Rejects Talc Settlement",
      "id": 133658175,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson shares tumbled Tuesday to lead S&P 500 decliners after the health care giant failed to reach a settlement in liability cases related to its baby powder and other talc products. Monitor these key chart levels.",
      "url": "https://finnhub.io/api/news?id=47043a379ca2efec2f1a18c86572c59fc8100e4510e2c7cbd21da8b38e899ada"
    }
  },
  {
    "ts": null,
    "headline": "Lord Abbett Affiliated Fund Q4 2024 Commentary",
    "summary": "The Fund returned 0.07% reflecting performance at the net asset value of Class I shares with all distributions reinvested for the quarter ended September 30, 2024.",
    "url": "https://finnhub.io/api/news?id=34fcbc832900af9ec3ffc7cc0967bc2183304e0d3b2ae4b0d7f90f6adcdb2610",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743552600,
      "headline": "Lord Abbett Affiliated Fund Q4 2024 Commentary",
      "id": 133657820,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1147550464/image_1147550464.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "The Fund returned 0.07% reflecting performance at the net asset value of Class I shares with all distributions reinvested for the quarter ended September 30, 2024.",
      "url": "https://finnhub.io/api/news?id=34fcbc832900af9ec3ffc7cc0967bc2183304e0d3b2ae4b0d7f90f6adcdb2610"
    }
  }
]